

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TEVA PHARMACEUTICALS USA, INC. AND WATSON
LABORATORIES, INC.

Petitioners,

v.

MERCK SHARP & DOHME CORP.

Patent Owner.

Case IPR2020-01045

Patent 7,326,708

PETITIONERS' UPDATED EXHIBIT LIST

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board

United States Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

<i>Petitioner Exhibit #</i>	<i>Description</i>
1001	U.S. Patent No. 7,326,708
1002	Declaration of Dr. Leonard Chyall
1003	CV of Dr. Leonard Chyall
1004	WO 03/004498 to Edmonson
1005	Brittain, "Polymorphism in Pharmaceutical Solids"
1006	Bastin et al. "Salt Selection and Optimisation [sic] Procedures for Pharmaceutical New Chemical Entities"
1007	U.S. Patent No 6,699,871
1008	Orange Book Entry for Janumet®
1009	Orange Book Entry for Januvia®
1010	Complete copy of the prosecution history of the '708 patent as available for download from the USPTO website
1011	U.S. Patent No. 4,572,909
1012	U.S. Provisional Application No. 60/303,474, filed July 6, 2001
1013	Prescribing Information for Janumet®
1014	Prescribing Information for Januvia®
1015	Merck Sharpe & Dohme's Responses and Objections to Defendants' First Set of Joint Interrogatories (1-10)
1016	Brown et al., Chemistry: The Central Science, 8th Revised Edition 615-618 (2002)
1017	<i>Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.</i> , IPR2020-00040, Ex. 1002, Declaration of Dr. Mukund Chorghade, Ph.D. (Oct. 29, 2019)
1018	Declaration of Emily L. Rapalino in Support of Petitioners' Motion for <i>Pro Hac Vice</i> Admission of Emily L. Rapalino Under 37 C.F.R. § 42.10(c)
1019	Email from Merck to Joinder Petitioners Regarding Silent Understudy Conditions
1020	Complaint, <i>Merck Sharp & Dohme Corp. v. Dr. Reddy's Laboratories, Inc. et al.</i> , No. 1:20-cv-00847-RGA, ECF 1 (D. Del. June 24, 2020)
1021	Decision, State of Israel Commissioner of Patents, Designs and Trademarks, Teva Pharmaceutical Industries Ltd. Opposition to Merck Sharp & Dohme Corp. Patent Application No. 172563 (July 30, 2019)
1022	Third Declaration of Leonard J. Chyall, Ph.D.

Case IPR2020-01045

Patent 7,326,708

<i>Petitioner Exhibit #</i>	<i>Description</i>
1023	Settlement Agreements [Parties and Board Only]

Dated: November 24, 2020

Respectfully submitted,

/Keith A. Zullo/

Keith A. Zullo

(Reg. No. 37,975)

Goodwin Procter LLP

The New York Times Building

620 Eighth Avenue

New York, NY 10018-1405

Tel: 212-813--8800

Fax: 212-355-3333

kzullo@goodwinlaw.com

*Lead Counsel for Petitioners Teva
Pharmaceuticals USA, Inc. and Watson
Laboratories, Inc.*

CERTIFICATION OF SERVICE

Pursuant to 37 C.F.R. §§ 42.6(e) and 42.8(b)(4), the undersigned hereby certifies that the above-captioned “PETITIONERS’ UPDATED EXHIBIT LIST” was served electronically via e-mail on November 24, 2020 on the following counsel of record:

Stanley E. Fisher
Bruce R. Genderson
Jessamyn S. Berniker
Alexander S. Zolan
Elise M. Baumgarten
Shaun P. Mahaffy
Anthony H. Sheh
WILLIAMS & CONNOLLY LLP
725 Twelfth Street, N.W.
Washington, DC 20005
T: (202) 434-5000
F: (202) 434-5029
sfisher@wc.com
bgenderson@wc.com
jberniker@wc.com
azolan@wc.com
ebaumgarten@wc.com
smahaffy@wc.com
asheh@wc.com
MerckSitagliptin@wc.com

Dated: November 24, 2020

Respectfully submitted,

Goodwin Procter LLP

/Keith A. Zullo/

Keith A. Zullo (Reg. No. 37,975)
*Lead Counsel for Petitioners Teva
Pharmaceuticals USA, Inc. and Watson
Laboratories, Inc.*